Efficacy of Argon-Helium Cryoablation Plus PD-1 Inhibitors in NSCLC
Status:
COMPLETED
Trial end date:
2024-12-01
Target enrollment:
Participant gender:
Summary
This randomized controlled trial investigated the efficacy and safety of argon-helium cryoablation combined with PD-1 inhibitors compared to PD-1 inhibitors plus chemotherapy for treating non-small cell lung cancer (NSCLC). The study aimed to evaluate differences in survival, tumor response, immune function, and adverse events.